The target population of the PANNA study are HIV-infected pregnant women who have an indication for treatment with a cART regimen containing a newly developed antiretroviral agent for which there is insufficient data available on the pharmacokinetics during pregnancy. The selection of the antiretroviral agents is at the discretion of the treating physician.
Below you will find an overview of the antiretroviral agents that we will investigate in the PANNA study. The number of patients still needed is mentioned in the last column. Please contact the study centre near you to include a patient treated with one of these agents.
Drug name | Class | Dose and frequency |
# pt included | # patients needed (16-#included) |
---|---|---|---|---|
Bictegravir, Biktarvy®, BIC | II | 50mg QD | 3 | 14 |
Doravirine, Pifeltro®, Delstrigo®, DORA | NNRTI | 100mg QD | 0 | 16 |
Dolutegravir, Tivicay®, Triumeq®, DTG | II | 50mg QD | 21 | 2 |
Raltegravir, Issentress®, RAL | II | 1200mg QD | 3 | 13 |
Tenofovir alafenamide, Descovy®, Genvoya®, Odefsey®, TAF | NRTI | 10mg / 25mg QD | 22 | 6 |
Fosamprenavir, Telzir®, FPV | PI | 700mg/100mg RTV BID 1400mg/200mg RTV QD |
3 | 13 |
Enfuvirtide, Fuzeon® | entry inhibitor | 90mg BID | 2 | 14 |
Elvitegravir, Vitekta®, Stribild®, EVG | II | 150mg QD/85mg QD | 14 | 0, closed |
Cobicistat, in Stribild®, COBI | booster | 150mg QD | 14 | 0, closed |
Darunavir/cobi, Rezolsta® |
PI | 800mg/100mg DRV/COBI QD | 2 | 0, closed |
Rilpivirine, Edurant®, TMC278 | NNRTI | 25mg QD | 16 | 0, closed |
Abacavir, Ziagen® | NRTI | 300mg BID | 16 | 0, closed |
Emtricitabine, Emtriva® or FTC | NRTI | 200mg QD | 40 | 0, closed |
Tenofovir, Viread®, TDF | NtRTI | 245mg QD | 43 | 0, closed |
Efavirenz, Stocrin®, EFV |
NNRTI |
600mg QD |
16 |
0, closed |
Etravirine, Intelence®, TMC125 |
NNRTI |
200mg BID |
5 |
0, closed |
Atazanavir, Reyataz® | PI | 300/100mg RTV QD 400mgQD 400/100mg RTV QD |
30 | 0, closed |
Darunavir, Prezista®, TMC114 | PI | 600mg/100mg RTV BID 800mg/100mg QD |
24 | 0, closed |
Tipranavir, Aptivus®, TPV | PI | 500mg/200mg RTV BID | 0 | 16 |
Indinavir, Crixivan® | PI |
800mg TID 800mg/100mg RTV BID |
0 | 16 |
Raltegravir, Isentress® | integrase inhib | 400mg BID | 21 | 0, closed |
Maraviroc, Celsentri® | entry inhibitor | 300mg BID | 7 | 0, closed |